City of Hope, known for its robust integration of advanced scientific discovery and clinical application, has demonstrated a compelling commitment to pushing the frontiers of cancer care. At this year’s ASCO meeting, their contributions signal a pivotal evolution towards treatment paradigms that emphasize precision medicine — tailoring therapy based on individual genetic, molecular, and immunological profiles. The center’s physician-scientists are not only presenting data but will also lead critical sessions, panel discussions, and educational symposia, underscoring their leadership within the global oncology community.

Among the highlights is the phase 3 SUNMO trial, which investigates the efficacy and safety of mosunetuzumab combined with polatuzumab vedotin (Mosun-Pola) compared with the established rituximab, gemcitabine, and oxaliplatin regimen (R-GemOx) in relapsed/refractory large B-cell lymphoma (LBCL). The updated data dissect outcomes in second-line versus later-line treatment settings, providing nuanced insights that could influence clinical decision-making in lymphoma subtypes resistant to previous therapies. These findings stress the importance of bispecific antibodies and antibody-drug conjugates in overcoming therapeutic resistance mechanisms.

Another frontier explored by City of Hope’s research includes a first-in-human phase 1 study of ABBV-969, a novel therapeutic targeting metastatic castration-resistant prostate cancer (mCRPC). The investigation covers safety, pharmacokinetics, and preliminary efficacy metrics, aiming to carve a new pathway in prostate cancer management by exploiting molecular vulnerabilities unique to advanced disease phenotypes.

Intricately linking microbiome science with immuno-oncology, a standout study evaluates microbial dysbiosis as a biomarker predicting response to CBM588 when used alongside immune checkpoint blockade (ICB) therapies for metastatic renal cell carcinoma (mRCC). This innovative research adds a layer of complexity to personalizing cancer immunotherapies, suggesting that microbial ecosystem modulation could potentiate therapeutic efficacy and patient outcomes.

City of Hope’s commitment to combining molecularly targeted agents is further embodied in the randomized phase II SWOG S2001 trial, comparing the use of olaparib plus pembrolizumab with olaparib monotherapy as maintenance strategies in metastatic pancreatic cancer patients harboring germline BRCA1 or BRCA2 mutations. This trial hones in on synergistic immuno-genomic approaches to combat notoriously aggressive and refractory pancreatic tumors.

In parallel, dose-finding results emerging from a phase 1/2 study of tegavivint, a downstream Wnt/β-catenin pathway inhibitor, in advanced hepatocellular carcinoma (aHCC) highlight efforts to disrupt key oncogenic signaling nodes. Given the canonical Wnt pathway’s critical role in tumor proliferation and survival, these findings present promising avenues for targeting hepatobiliary malignancies often resistant to current interventions.

City of Hope does not merely contribute abstracts; it drives plenary discussions shaping contemporary oncology thought. For instance, the phase 3 LIBERTTO-432 trial evaluation of adjuvant selpercatinib in stage IB-IIIA RET fusion-positive non-small cell lung cancer (NSCLC) demonstrates improved event-free survival, emphasizing precision oncology’s expanding role even in early-stage disease.

Leading voices from City of Hope, such as Dr. Kristin Higgins, Chair and Moderator of a lung cancer case-based panel, dissect complex treatment pathways in ALK-positive NSCLC, navigating therapeutic decisions from early to advanced stages. Concurrently, hematologic malignancies expert Dr. Amrita Krishnan moderates critical discussion around treatment depth and risk in multiple myeloma, reflecting the center’s multifaceted expertise.

Immunotherapy continues to be a central theme with Dr. Tycel Phillips summarizing strategies to tailor immune interventions for relapsed lymphoma, reflecting the growing implications of bispecific antibodies, checkpoint inhibitors, and cellular therapies in refractory settings.

Prostate cancer management is also refined under City of Hope’s stewardship, as Dr. Tanya Dorff presents a comprehensive overview of personalized treatments spanning the entire disease spectrum, underscoring innovations that integrate genomic profiling, novel agents, and therapeutic sequencing.

The clinical exposition is complemented by educational sessions, such as those led by Dr. Charles Nguyen, who unpacks frontline therapeutic strategies in papillary renal cell carcinoma, a subtype demanding precise molecularly guided treatments.

City of Hope’s continued influence is mirrored by institutional honors, including Dr. John Carpten receiving the prestigious 2026 Allen Lichter Visionary Leader Award from ASCO. His groundbreaking work in cancer genomics and precision medicine has shaped strategic national research agendas and exemplifies the visionary leadership driving City of Hope’s mission.

The recognition extends to newly inducted Fellows of the American Society of Clinical Oncology (FASCO) from City of Hope, acknowledging sustained leadership and contributions in oncology care, research, and education. Drs. Arjun Gupta, Tanya Dorff, and Walter Stadler represent the breadth of expertise and dedication within this national oncology powerhouse.

City of Hope’s integrated approach, converging innovative research, clinical trials, and educational leadership, reinforces its position at the vanguard of oncology. Their expansive portfolio presented at ASCO 2026 not only charts the current science but shapes future paradigms designed to deliver therapies that are more personalized, tolerable, and efficacious.

The developments set forth by City of Hope’s research teams epitomize the crossroads of technological progress and medical ingenuity, heralding an era where cancer care transcends traditional boundaries and embodies tailored precision that elevates patient survival and quality of life.

As ASCO 2026 unfolds, City of Hope’s contributions are poised to inspire novel treatment algorithms, inform policy decisions, and galvanize the oncology community towards breakthroughs that reverberate across the spectrum of cancer biology and therapeutics.

Subject of Research: Cancer immunotherapy, precision medicine, novel therapeutic strategies, hematologic malignancies, solid tumors.

Article Title: City of Hope Scientists Unveil Pioneering Advances in Cancer Treatment at ASCO 2026.

News Publication Date: 2026.

Web References: https://www.cityofhope.org/asco-2026

Keywords: Immunotherapy, Precision Medicine, Metastatic Cancer, Hematologic Malignancies, Bispecific Antibodies, Cancer Genomics, Clinical Trials, Biomarkers, Wnt/β-catenin Inhibition, Immune Checkpoint Blockade, Prostate Cancer, Pancreatic Cancer.

At the core of this revolutionary therapy lies the ability to harness the body’s own immune system by selecting and expanding TILs, which are immune cells that infiltrate tumors and can specifically recognize and attack cancer cells. In precise terms, researchers isolate these TILs from a tumor biopsy, where they are often found in large numbers yet remain ineffective in eliminating the tumor. Once these cells are harvested, they are cultivated in a laboratory setting where they can proliferate to substantial quantities before being reintroduced to the patient’s body.

In this clinical trial, which involved a diverse group of 91 patients suffering from various advanced forms of gastrointestinal malignancies—ranging from esophageal and stomach cancers to pancreas and colon cancers—the researchers administered this newly refined TIL therapy in conjunction with the immune checkpoint inhibitor pembrolizumab, known widely as Keytruda. This combination aims to counter the tumor’s protective mechanisms that typically allow it to evade immune detection, thus enhancing the therapeutic effects of TILs.

Dramatic results emerged from the trial, as nearly 24% of participants receiving selected TILs alongside pembrolizumab demonstrated significant tumor shrinkage, a stark contrast to the 7.7% response rate observed in patients treated with TILs alone. This suggests that the simultaneous application of TILs and an immune checkpoint inhibitor may indeed optimize treatment efficacy, setting the stage for future investigative efforts into combination therapies.

Dr. Steven A. Rosenberg, M.D., Ph.D., the lead investigator of the study and a pioneer in the field of cancer immunotherapy, expressed enthusiasm about the results, noting, “We’re witnessing the first extension of TIL therapy into common solid tumors. These findings indicate a potential breakthrough, allowing for the opening of what has been deemed an impenetrable wall of cancer.” This perspective underscores the scientific community’s ongoing commitment to understanding the intricate mechanisms of immune evasion employed by tumors.

The design of the clinical trial consisted of three distinct phases, enabling researchers to systematically evaluate the performance of different treatment strategies. In the initial pilot phase, 18 patients received TILs that were not selected based on their anti-tumor properties, resulting in no objective tumor responses. However, subsequent phases unveiled a different scenario; 39 patients treated with selected TILs experienced some level of tumor response, leading researchers to explore advanced methodologies to enhance therapeutic outcomes.

The most notable findings arose in the trial’s third phase, where 34 patients received pembrolizumab prior to the infusion of selected TILs. This tactical approach aimed to prime the immune system, safeguarding the newly introduced TILs from being rendered ineffective by the patient’s existing immune response. Remarkably, this cohort boasted an objective response rate of 23.5%, illuminating the possibility that strategic combinations of immunological interventions could revolutionize treatment pathways for solid tumors.

Importantly, the study noted that serious side effects occurred in approximately 30% of individuals treated with selected TIL therapy, highlighting the necessity for continued vigilance in monitoring patients undergoing such innovative treatments. The varying response rates among different tumor types, including colorectal and pancreatic cancers, further indicated the complexities inherent to cancer biology—underscoring why personalized therapies are so critically needed in modern oncology.

As this exploratory research volume expands, the design of future studies will likely involve not only the optimization of TIL therapies but also the identification of neoantigens—specific proteins that tumors express and that may provoke an immune response—aimed at tapping into a broader spectrum of therapeutic targets for patients. Such strategies may enhance the breadth of responses to TIL therapy while mitigating potential resistance mechanisms employed by malignancies.

TIL therapy, which gained traction in the late 1980s, has evolved remarkably since its inception, with the FDA’s recent approval of lifileucel (Amtagvi), the first TIL therapy to treat advanced melanoma, marking a pivotal moment in cancer treatment nutrition. As researchers at NIH continue to refine and adapt existing methodologies, their approach represents a paradigm shift in the treatment landscape of solid cancers, one characterized by hope, innovation, and aggressive advancement.

The collaboration between various experts, including Dr. Rosenberg, Dr. Frank J. Lowery, and Dr. Stephanie L. Goff at NCI, underscores the importance of interdisciplinary research in overcoming oncological barriers. Their collective commitment to advancing cancer therapies emphasizes the collaborative spirit that is imperative for fostering groundbreaking discoveries in the field.

As TIL therapy gains momentum, it stands poised to reach beyond gastrointestinal cancers, potentially offering new avenues for a myriad of solid tumors—an outcome that could redefine treatment standards and improve the quality of life for countless patients navigating cancer. With this trajectory, continuous research and innovation remain necessary as the community strives to realize the full potential of immunotherapeutic strategies.

The extensive implications of this study extend beyond immediate patient outcomes, setting a solid groundwork for future research endeavors aimed at broadening the therapeutic scope of TILs. Through dedicated efforts, the prospects of harnessing the immune system to combat cancer represent a burgeoning frontier in modern medicine, stirring anticipation for the changes that lie ahead in cancer treatment protocols.

With each stride taken in the journey to unveil the complexities of TILs and immune responses, the scientific community remains enthusiastic about the prospects of personalized cancer immunotherapy. As these paradigms shift, they inevitably cultivate a landscape filled with hope, where innovative strategies and renewed resolve position the fight against cancer on a more formidable battlefield.

In conclusion, the potential of selected TIL therapy alongside pembrolizumab heralds a transformative phase in oncological treatment. As researchers continue to explore the intricate dimensions of this immunotherapeutic strategy, the horizon holds the promise of more effective, targeted treatment methodologies that could write a new chapter in the annals of cancer care, ultimately leading to a future where cancer is not only manageable but conquerable.

Subject of Research: Selected Tumor-Infiltrating Lymphocyte Therapy in Gastrointestinal Cancers
Article Title: Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial
News Publication Date: 1-Apr-2025
Web References: Nature Medicine DOI
References: Research conducted at the National Cancer Institute
Image Credits: Center for Cancer Research/National Cancer Institute

Keywords: Cancer, Immunotherapy, Tumor Infiltrating Lymphocyte, Gastrointestinal Cancer, Personalized Therapy.

The efficacy of immune therapies has been a beacon of hope for many cancer patients, particularly with the emergence of checkpoint inhibitors that empower the immune system to identify and destroy cancer cells. Nonetheless, the limitations of these therapies are starkly evident in solid tumors. Tumor microenvironments are often characterized by nutrient deprivation, elevated acidity, and hypoxic (low oxygen) conditions, all of which lead to T cell exhaustion and hinder their anti-tumor functions. In high-mortality cancers, such as pancreatic cancer, this hostile environment becomes even more damaging, rendering conventional immunotherapies less effective.

Dr. Samantha Pretto, the lead author of the study, emphasizes a pivotal question: “What if we can reprogram T cells so that they can use a different nutrient?” Her sentiment reflects a paradigm shift in thinking about T cells not merely as reactive agents of the immune system, but as adaptable entities capable of metabolic reengineering. The research team diligently focused on the biochemical pathways that regulate T cell activity, with the objective of identifying strategies to support T cell survival and efficacy in the challenging contexts of solid tumors.

Central to their findings is the enzyme Elovl1, which they identified as a critical target for metabolic intervention in T cells. By inhibiting Elovl1, the researchers enabled T cells to switch from glucose metabolism, which is often compromised within tumors, to fatty acid oxidation. This metabolic maneuver not only enhances the energy efficiency of T cells but also fortifies their proliferation and anti-tumor capabilities. The ability of T cells to persist longer within tumors signifies a substantial leap toward improving patient outcomes—a concept previously deemed elusive.

The implications of this metabolic reprogramming extend beyond mere survival in adverse conditions; they enhance the arsenal of T cells in mounting a formidable defense against cancer cells. Professor Max Mazzone, a co-author of the study, articulates the significance of the research: “This study offers a genetic analysis of multiple metabolic pathways at the primary tumor and metastatic sites, disclosing how altering these pathways can empower T cell phenotypes.” By documenting the metabolic transformations and their impact on T cell behavior, the research paves the way for developing more effective immunotherapeutic strategies.

Encouragingly, the researchers demonstrated that the combination of Elovl1 blockade with current immune checkpoint therapies resulted in striking improvements in T cell responses within preclinical models of melanoma and pancreatic cancer. This synergistic effect showcases a novel strategy to outsmart the inherent defenses of tumors, amplifying the potential for successful treatment outcomes. Such findings are pivotal, as they not only boost the efficacy of therapies but also provide hope for patients who have exhausted available treatment options.

The study instigates critical discussions about the future of cancer treatment, particularly regarding metabolic manipulation of immune cells. Traditional approaches have predominantly emphasized restoring immune recognition through checkpoint modulation. However, this new insight brings to light the necessity to consider the metabolic state of immune cells as a fundamental component in enhancing their functionality. Understanding these metabolic dynamics could lead to the development of treatments that are not only more effective but also uniquely suited to individual patient profiles.

As research continues to evolve, the potential for transforming cancer therapy through metabolic reprogramming appears boundless. By tapping into the intricacies of cellular metabolism, scientists can forge pathways that not only improve T cell endurance and lethality against tumors but also complement existing therapies, optimally matching therapeutic strategies to the metabolic profiles of different tumor types. The potential applications of this research may extend well beyond solid tumors, offering insights into a myriad of cancers characterized by similar immune evasion strategies.

In summary, the work of the VIB-KU Leuven team represents a vital intersection of immunology and metabolism, a fusion that could unlock new frontiers in cancer therapy. As we look to the future, the prospect of successfully harnessing the power of our immune system through such innovative approaches is not only promising—it is essential. This study serves as a testament to the relentless pursuit of scientific discovery in the face of one of humanity’s most formidable challenges.

In conclusion, the findings from this ambitious research initiative underscore the importance of metabolic flexibility in enhancing the capabilities of T cells. By engineering T cells to adapt to their environment through metabolic reprogramming, we envisage a future in which cancer therapies are not just about targeting tumors but also about empowering the immune system to function optimally. The journey toward unlocking the full potential of immunotherapy is, indeed, one marked by innovation, with researchers continually striving to pave the way for breakthroughs that could transform lives in the fight against cancer.

Subject of Research: Animals
Article Title: A functional single-cell metabolic survey identifies Elovl1 as a target to enhance CD8+ T cell fitness in solid tumours
News Publication Date: 10-Mar-2025
Web References: http://dx.doi.org/10.1038/s42255-025-01233-w
References: Not applicable
Image Credits: Not applicable

Keywords: Solid tumors, T lymphocytes, Cell therapies, Primary tumors, Immune system